NCT02530411
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Endocrine (Hormone) Therapy
Key Eligibility Criteria:
Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases:
Additional Notes: Must have ER+ tumor (s)
Exclusions: Symptomatic or unstable brain/meningeal metastases; Prioir treatment with fulvestrant
https://ClinicalTrials.gov/show/NCT02530411